Department of Digestive and Oncological Surgery, University of Lille, Claude Huriez University Hospital, Lille, France.
Institute of Pathology, Lille University Hospital, Lille, Cedex, France.
Ann Surg Oncol. 2021 Dec;28(13):8337-8346. doi: 10.1245/s10434-021-10707-6. Epub 2021 Sep 13.
Two definitions of a positive circumferential resection margin (CRM) in esophageal cancer coexist: one by the College of American Pathologists (CAP) (CRM = 0 mm) and another by the Royal College of Pathologists (RCP) (CRM ≤ 1 mm). This study aimed to evaluate the prognostic value of both definitions in esophageal cancer and to identify a new cutoff value for the CRM to predict survival.
Patients who underwent curative esophageal resection for locally advanced (≥ pT3) adenocarcinoma or squamous cell carcinoma were selected from 2007 to 2016. The CRM was reassessed using an ocular micrometer. Overall survival (OS) and disease-free survival were estimated with uni- and multivariate analyses.
The study enrolled 283 patients: 48 with a positive CRM according to the CAP definition and 171 with a positive CRM according to the RCP definition. In the multivariate analysis, a positive CRM according to both definitions was significantly associated with a poor OS (CAP: hazard ratio [HR], 2.26, p < 0.001; RCP: HR, 1.42, p = 0.035). A CRM of 0 mm was predictive of a worse OS and DFS than a CRM of 1 mm or less (p < 0.0001), whereas no significant difference was found between a CRM greater than 1 mm and a CRM of 1 mm or less, indicating that the CAP definition was more accurate for predicting prognosis and recurrence. New cutoff CRM values of 100 µm in squamous cell carcinoma and 200 µm in adenocarcinoma were optimal for predicting OS.
The CAP definition was more accurate for predicting prognosis and recurrence. The study identified a new cutoff value of CRM according to histologic type.
两种食管癌环周切缘阳性(CRM)的定义并存:美国病理学家学院(CAP)的定义(CRM=0mm)和皇家病理学家学院(RCP)的定义(CRM≤1mm)。本研究旨在评估这两种定义在食管癌中的预后价值,并确定一个新的 CRM 截止值来预测生存。
从 2007 年至 2016 年,选择接受根治性食管切除术治疗局部晚期(≥pT3)腺癌或鳞癌的患者。使用目镜测微器重新评估 CRM。采用单因素和多因素分析估计总生存期(OS)和无病生存期。
该研究共纳入 283 例患者:48 例根据 CAP 定义为 CRM 阳性,171 例根据 RCP 定义为 CRM 阳性。多因素分析显示,两种定义的 CRM 阳性均与 OS 不良显著相关(CAP:危险比[HR],2.26,p<0.001;RCP:HR,1.42,p=0.035)。CRM 为 0mm 预测 OS 和DFS 均差于 CRM 为 1mm 或更小(p<0.0001),而 CRM 大于 1mm 与 CRM 为 1mm 或更小之间无显著差异,表明 CAP 定义更准确地预测预后和复发。鳞癌的新 CRM 截止值为 100μm,腺癌的新 CRM 截止值为 200μm,最有利于预测 OS。
CAP 定义更准确地预测预后和复发。本研究根据组织学类型确定了新的 CRM 截止值。